In the mouse model of ACD, rosmarinic acid has been demonstrated to attenuate ACD manifestations and suppress non-histaminergic pruritus by inhibiting MRGPRX2-mediated MC degranulation to CST-14 and by reducing levels of the proinflammatory cytokine IL-13 in mouse tissues [72,74]. The gene discussed is MRGPRX2; the disease is granular corneal dystrophy type II.